Aptamer 学术简报 — cancer — 2026-09-12

自动生成 by RBTX Aptamer Tracker v0.1。 子主题 cancer：近 14 天 53 篇命中（aptamer 池 230 篇）。

评分公式：composite = 0.45×log(IF) + 0.35×log(cites_velocity) + 0.10×social + 0.10×recency_bonus；满分 100。

#1 [15.6] AuPt bimetallic nanocatalyst-amplified luminol-dissolved oxygen electrochemiluminescence for interferon-γ immunosensing

Interferon-γ (IFN-γ) is a pivotal inflammatory cytokine whose abnormal expression is associated with autoimmune disorders, infectious diseases, and cancer. Herein, a signal-off electrochemiluminescence (ECL) immunosensor was developed by integrating catalytic signal amplification with oriented antibody immobilization. An amino-functionalized ver...

#2 [14.3] Self-Enhancing Photodynamic / Immunotherapy via a MOF Nanoplatform for Combined STING Activation and Immune Checkpoint Blockade.

Combinational photodynamic and immune checkpoint blockade (PDT/ICB) therapy is a promising approach for oncotherapy. However, the tumor microenvironment (TME) poses multiple biological barriers that can critically undermine the treatment outcomes of PDT/ICB. To this end, a cascade-amplified photodynamic immunotherapy nanoplatform based on the co...

#3 [13.4] Folic acid-anchored liposomes in cancer therapy: a next-generation nanoplatform for precision drug delivery and tumor targeting.

Targeted drug delivery (TDD) has emerged as a potential strategy for cancer management by selectively delivering therapeutic agents directly to the targeted site. The current trends in TDD for cancer therapy, focus on the use of various ligands, such as hyaluronic acid, folic acid (FA), carbohydrates, peptides, antibodies, and aptamers to enhanc...

#4 [12.8] Identification of melanotransferrin (MFI2) as a membrane target and an MFI2-directed aptamer as a theranostic tool for pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and limited targeted therapeutic options. Melanotransferrin (MFI2) is a membrane-anchored protein that we found to be significantly upregulated in PDAC tissues and cell lines. MFI2 knockdown markedly reduced cell proliferation, migration, invasion, and epithelial-mesenchy...

#5 [12.7] Aptamer-Functionalized DNA Frameworks as Targeted Drug Buffers for Concentration Regulation of Maytansine.

Traditional chemotherapy often suffers from nonspecific distribution and poor drug concentration control, leading to compromised therapeutic efficacy and adverse effects. Mertansine (DM1), a potent cytotoxic agent with poor selectivity, dose-limiting toxicity, and a narrow therapeutic window, demands targeted delivery and precise concentration r...

#6 [12.7] Single-Exosome EpCAM Heterogeneity Profiling for Breast Cancer Diagnosis and Progression Monitoring.

Exosomes are nanoscale vesicles that are attractive for liquid biopsy, but most methods deliver ensemble averages and obscure how surface biomarkers vary across individual vesicles. We develop a single-particle impact electrochemistry (SPIE) assay to profile epithelial cell adhesion molecule (EpCAM) on single exosomes. EpCAM-positive vesicles ar...

#7 [12.3] Cell-Surface-to-Solution Signal Transduction via a CRISPR/Cas12a-Based Dual-Target Aptamer Sensor for Detecting Urothelial Carcinoma Cells in Urine

Abstract Urothelial carcinoma (UC) is a common malignancy of the genitourinary system with high recurrence rates, requiring non-invasive postoperative monitoring. Direct detection of exfoliated UC cells in urine can provide tumor-origin evidence but remains challenging because of low target-cell abundance, complex urine interference, and subject...

#8 [12.1] Co-profiling of exosomal proteins and microRNAs using single microbead confinement for breast cancer diagnosis.

Tumor-derived exosomes (TEXs) hold immense promise as biomarkers for cancer diagnosis, but sensitive and accurate identification is hindered by their intrinsic heterogeneity and extreme scarcity. Co-profiling of exosomal protein and microRNA (miRNA) at the single-molecule level may greatly enhance the precision of cancer diagnosis and prognosis....

#9 [12.0] Multivariate-Activated DNA Logic Gate for Predicting Responses to Cisplatin-Based Chemotherapy

Abstract Cisplatin-based chemotherapy remains an attractive alternative for controlling advanced cancers. However, a subset of cancer patients exhibits resistance to cisplatin. Accurate and early prediction of individual responses to cisplatin treatment is critical to personalized medicine guidance. The development of an effective method to pred...

#10 [11.9] Targeted Strategies for Treatment of Colorectal Cancer: Exploring the Use of Aptamers and Gold Nanoparticles

Colorectal cancer (CRC) is the second leading cause of cancer-associated mortality and accounts for ~10% of all cancer cases. Global CRC cases were estimated at 1.9 million and 930,000 deaths in 2022. Despite improved access to CRC screening and treatment, death rates are expected to drastically increase in low-resource areas, highlighting an ur...

Methodology